Get the Stockscreener App
2.08
1.96%
0.04
After Hours:
2.08
Armata Pharmaceuticals Inc stock is traded at $2.08, with a volume of 5,960.
It is up +1.96% in the last 24 hours and up +0.48% over the past month.
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections in the United States. The company develops its products using its proprietary bacteriophage-based technology. Its product candidate is the AP-SA01 that targets Staphylococcus aureus, including multidrug-resistant strains. The company is also developing and advancing synthetic phage for treating diseases caused by pseudomonas aeruginosa. Armata Pharmaceuticals, Inc. is headquartered in Marina del Rey, California.
See More
Previous Close:
$2.04
Open:
$2.12
24h Volume:
5,960
Relative Volume:
0.54
Market Cap:
$76.71M
Revenue:
-
Net Income/Loss:
$-41.36M
P/E Ratio:
-1.2683
EPS:
-1.64
Net Cash Flow:
$-42.09M
1W Performance:
+4.00%
1M Performance:
+0.48%
6M Performance:
-18.27%
1Y Performance:
-44.97%
1-Day Range:
$2.00
$2.12
1-Week Range:
$1.97
$2.12
52-Week Range:
$1.80
$4.48
Armata Pharmaceuticals Inc Stock (ARMP) Company Profile
Name
Armata Pharmaceuticals Inc
Sector
Industry
Phone
310-655-2928
Address
4503 Glencoe Avenue, Marina del Rey, CA
Compare ARMP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARMP
Armata Pharmaceuticals Inc
|
2.08 | 76.71M | 0 | -41.36M | -42.09M | -1.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.32 | 122.13B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
710.00 | 78.30B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
646.64 | 39.73B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.19 | 35.50B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.61 | 28.47B | 3.30B | -501.07M | 1.03B | -2.1146 |
Armata Pharmaceuticals Inc Stock (ARMP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-19-19 | Initiated | Ladenburg Thalmann | Buy |
Armata Pharmaceuticals Inc Stock (ARMP) Latest News
Short Interest in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Grows By 203.3% - MarketBeat
10 Best Healthcare Stocks to Invest In (February 2025) - Securities.io
Chronic Pulmonary Infections Pipeline 2024: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Teva Pharma, Merck, F. Hoffmann-La Roche, Novartis, GlaxoSmithKline, AstraZeneca - The Globe and Mail
Phage Therapies Clinical Trial Pipeline Shows Potential with Active Contributions from 20+ Key Companies | DelveInsight - GlobeNewswire Inc.
Armata Pharmaceuticals (STU:TG1N) PS Ratio : (As of Jan. 14, 2025) - GuruFocus.com
Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Short Interest Update - MarketBeat
Armata Pharmaceuticals Announces $35 Million Secured Credit Agre - GuruFocus.com
Short Interest in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Grows By 125.9% - MarketBeat
Ampliphi Biosciences (NYSEAMERICAN:APHB) Announces Positive Results from Phase 2 Tailwind Study - Defense World
Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Earns “Buy” Rating from HC Wainwright - Defense World
Armata Pharma’s inhaled AP-PA02 shows positive results in Phase 2 study - Yahoo Finance
Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Given Buy Rating at HC Wainwright - MarketBeat
Armata Pharmaceuticals Reports Positive Phase 2 Study Results - TipRanks
Armata Pharmaceuticals Announces Encouraging Results from the Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection - PR Newswire
ARMP Stock Touches 52-Week Low at $1.98 Amid Market Challenges - Investing.com
Suparna Mishra Sarkar - Los Angeles Times
Armata Pharmaceuticals Announces the Completion of Enrollment of its Phase 1b/2a diSArm Study Evaluating Intravenous AP-SA02 as a Potential Treatment for Staphylococcus aureus Bacteremia - The Eastern Progress Online
Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 5th Annual Phage Futures Annual Meeting - The Eastern Progress Online
Armata Pharmaceuticals Announces Appointment of Life Sciences Accounting and Finance Veteran David House as SVP of Finance and Principal Financial Officer - The Eastern Progress Online
Armata Pharmaceuticals Announces Presentation at the 6th Annual Bacteriophage Therapy Summit - GuruFocus.com
Armata Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 - Marketscreener.com
Armata Pharmaceuticals Announces Third Quarter 2024 Results and Provides Corporate Update - GuruFocus.com
Armata Pharmaceuticals, Inc. (ARMP) Reports Q3 Loss, Tops Revenue Estimates - MSN
Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 5th Annual Phage Futures Annual Meeting – Company AnnouncementFT.com - Financial Times
Armata Pharmaceuticals FY2024 EPS Raised by HC Wainwright - MarketBeat
Armata Pharmaceuticals Extends Credit Agreement and CMO Departs - TipRanks
HC Wainwright Reiterates “Buy” Rating for Armata Pharmaceuticals (NYSEAMERICAN:ARMP) - Defense World
Armata Pharmaceuticals Reports $3M Revenue, Advances Key Clinical Trials in Q3 | ARMP Stock News - StockTitan
Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Given "Buy" Rating at HC Wainwright - MarketBeat
Armata Pharmaceuticals Announces Structural Biology Publication - PR Newswire
Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Sees Large Decline in Short Interest - MarketBeat
Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Shares Down 2.2%Should You Sell? - MarketBeat
Armata Pharmaceuticals VP Richard Rychlik Departs with Benefits - TipRanks
Armata Pharmaceuticals announces executive departure - Investing.com
Arkema S.A. (OTCMKTS:ARKAY) Sees Large Growth in Short Interest - MarketBeat
Comparing ARS Pharmaceuticals (NASDAQ:SPRY) & Actinium Pharmaceuticals (NYSE:ATNM) - Defense World
Confronting Oropouche: a new stage for Cuban science - Radio Cadena Agramonte
Alto Neuroscience's Market Cap Drops To US$358m Leaving Insiders With Losses - Simply Wall St
American Century Companies Inc. Purchases 8,841 Shares of Armstrong World Industries, Inc. (NYSE:AWI) - MarketBeat
The Attractiveness of Investing In Artiva Biotherapeutics Inc (ARTV) is Growing - Knox Daily
ANRO’s latest rating updates from top analysts. - Knox Daily
ARKO Corp. (ARKO) Stock Slides as Market Rises: Facts to Know Before You Trade - Yahoo Finance
Art’s-Way Manufacturing (NASDAQ:ARTW) Now Covered by StockNews.com - Defense World
Dimensional Fund Advisors LP Has $193.14 Million Position in Archrock, Inc. (NYSE:AROC) - Defense World
Your Safety First: What You Need to Know About Bionpharma’s Urgent Atovaquone Recall - MyChesCo
Building Materials Stocks Q2 Results: Benchmarking Armstrong World (NYSE:AWI) - Yahoo Finance
Aurora Biosynthetics launch set to revolutionise RNA Therapeutics - Manufactures Monthly
Amplia Therapeutics’ Drug Fast-Tracked by FDA - TipRanks
Atovaquone Oral Suspension Recall Issued Due to Bacterial Contamination Risks - AboutLawsuits.com
Burgundy Asset Management Ltd. Purchases 17,075 Shares of Armstrong World Industries, Inc. (NYSE:AWI) - MarketBeat
Armata Pharmaceuticals Announces Presentation at Phage Futures: Global Digital Summit 2023 - GuruFocus.com
Armata Pharmaceuticals Inc Stock (ARMP) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):